NOX
NOXOPHARM FPO [NOX]
Healthcare · ASX Small Cap
$0.0730 +4.3%
Updated 9 Sep 2026 · Signals refresh every scan
Appeared in 5 consecutive scansFirst seen: 2026-02-25
Get alerts when NOX triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- RSI drifting toward oversold territory — worth watching
- Stochastic is deep in oversold territory — bounce conditions forming
- Volume surging at 3.6x normal while price climbs — real buying conviction behind this move
- Drifting lower — down 8.7% over the last 5 days
- Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
- Critical cash runway (0.4 quarters)
- Small-cap ($20-100M)
- Sentiment is mixed — no strong consensus either way
- The bigger volume days are the up days — volume-weighted momentum is positive (1.89%/day)
- Altman Z-Score grey zone (2.44, low-confidence approx)
- RBA hiking (-3pts)
Risk Signals
- Trading below both moving averages — the trend is working against this one
- Below the 200-day average — the long-term trend is still working against it
- Piotroski F-Score weak (2/9, low-confidence approx)
- Not enough chatter to gauge sentiment — defaulting to neutral
Expected next for NOX
Window: 26 Oct to 9 Nov
The last 9 moved NOX -0.9% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →
Recent Catalysts
LOW Investor Presentation September 2026
LOW Novel oligonucleotides data presented at Options Conference
NONE Appendix 4E - Preliminary Financial Report
NONE New preclinical data supports immuno-oncology approach
NONE New study further validates Noxopharms cancer pipeline
Recent ASX Announcements
| 2026-09-03 | Investor Presentation September 2026 |
| 2026-08-31 | Novel oligonucleotides data presented at Options Conference PRICE SENSITIVE |
| 2026-08-28 | Appendix 4E - Preliminary Financial Report PRICE SENSITIVE |
| 2026-08-25 | New preclinical data supports immuno-oncology approach PRICE SENSITIVE |
| 2026-08-03 | New study further validates Noxopharms cancer pipeline |
Key Metrics
$21.5M
Market Cap
103K
Avg Volume
3.6x
Vol Ratio
$0.05 — $0.11
52-Week Range
N/A
Short Interest
N/A
Cash Runway
N/A
ROE
N/A
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 66% |
| L | Leader vs Laggard | laggard | RS: -3 |
| I | Institutional Sponsorship | insufficient_data | Inst: 0% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
110 tickers in this sector
View all Healthcare signals →Browse all ASX tickers A–Z →Track NOX and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required